Effects of montelukast sodium tablets combined with salmeterol xinafoate and fluticasone propionate powder on inflammatory response and airway remodeling in patients with asthma-chronic obstructive pulmonary disease overlap syndrome
Objective To investigate the effects of montelukast sodium tablets combined with salmeterol xinafoate and fluticasone propionate powder on inflammatory response and airway remodeling in patients with asthma-chronic obstructive pulmonary disease overlap syndrome(ACOS).Methods A total of 80 patients with ACOS admitted in our hospital from January 2019 to December 2021 were selected as the research objects.According to the parity of admission number,the patients were divided into control group and observation group,with 40 cases in each group.The control group was treated with salmeterol xinafoate and fluticasone propionate powder for inhalation,and the observation group was treated with montelukast sodium tablets on the basis of the control group.The therapeutic effects of the two groups were compared.Results After treatment,the peak expiration flow(PEF),maximum voluntary ventilation(MVV),forced expiratory volume in one second(FEV1),forced vital capacity(FVC)and FEV1/FVC in the observation group were significantly higher than those in the control group(P＜0.05).After treatment,the airway peak pressure,expiratory pressure,inspiratory pressure and airway resistance in the observation group were significantly lower than those in the control group(P＜0.05).After treatment,the levels of C-reactive protein(CRP),chitinase-3-like protein 1(CHI3L1),hypoxia inducible factor-1α(HIF-1α)and intercellular adhesion molecule-1(ICAM-1)in the observation group were lower than those in the control group(P＜0.05).After treatment,the airway wall thickness(T)and wall thickness to airway diameter ratio(T/D)in the observation group were significantly higher than those in the control group,the area of airway(AI),total airway cross sectional area(AO)and percentage wall area for bronchial external diameter(WA%)were significantly lower than those in the control group(P＜0.05).Conclusion Montelukast sodium tablets combined with salmeterol xinafoate and fluticasone propionate powder can significantly improve the therapeutic effect of ACOS patients,improve airway inflammation and airway remodeling,and has important application value.
montelukast sodium tabletsalmeterol xinafoate and fluticasone propionate powder for inhalationasthma-chronic obstructive pulmonary disease overlap syndromelung function
万方数据
维普
